Opinion|Videos|November 19, 2026

Clinical Scenario: Treatment Selection at First Relapse in Multiple Myeloma

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss treatment selection for a 64-year-old man with multiple myeloma who experiences relapse nearly three years after autologous stem cell transplantation and lenalidomide maintenance following VRd induction.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss treatment selection for a 64-year-old man with multiple myeloma who experiences relapse nearly three years after autologous stem cell transplantation and lenalidomide maintenance following VRd induction. The patient is lenalidomide-refractory but has good performance status and has not received a CD38-targeted antibody or BCMA-directed therapy. Dr. Goldsmith emphasizes the importance of individualized treatment discussions that balance efficacy, safety, potential adverse effects, patient preferences, and practical considerations, including time away from work for CAR T-cell therapy or bispecific antibody treatment. He explains that incorporating CELMoDs into earlier-line treatment strategies may preserve additional options for subsequent relapse while offering a potentially more manageable treatment experience. Given the patient's clinical profile and treatment history, the experts discuss the rationale for considering iberdomide with daratumumab and dexamethasone. Dr. Mikhael reinforces the importance of selecting an appropriate therapy for the patient's current needs rather than automatically reserving a preferred treatment for a later line.


Related to this article